Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Progestogen with antiandrogenic properties used in the treatment of hypersexuality, prostate cancer, transsexuality (transsexual women) and, together with ethinylestradiol, in hirsutism, acne and hyperandrogenism, polycystic ovary syndrome and alopecia in women.
At a daily dose of 50 mg, it is excreted in breast milk in very small amounts: RID < 1% (Stoppelli 1980), and no antiandrogenic effects have been reported in infants.
The small amount (2 mg) found in contraceptive tablets in which it is combined with ethinylestradiol or estradiol would have a very low risk and would be compatible with breastfeeding.